Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. - Burstein,H.J.; Sun,Y.; Tan,A.R. (Cancer Res, 2009)